Infant Bacterial Therapeutics
98.4 SEK 0%Be the first to follow this company
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IBT B
Daily low / high price
98.4 / 99
SEK
Market cap
1.33B SEK
Turnover
2.36M SEK
Volume
24K
Financial calendar
Interim report
28.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
SIX SIS AG, W8IMY | 11.0 % | 8.4 % |
Fjärde AP-fonden | 10.0 % | 7.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools